Figura clau en el progrés de l'oncologia mundial i pioner en el desenvolupament de les teràpies moleculars que han salvat milers de vides
Obra Publicada
Selecció de publicacions:
- Baselga, José, et al. 'Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.' New England Journal of Medicine 366.2 (2012): 109-119.
- Baselga, José, et al. 'Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.' The Lancet 379.9816 (2012): 633-640.
- Higgins, Michaela J., and José Baselga. 'Targeted therapies for breast cancer.' The Journal of clinical investigation 121.10 (2011): 3797-3803.
- Baselga, José, et al. 'Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer.' Journal of Clinical Oncology 27.16 (2009): 2630-2637.
- Baselga, Jose, and Sandra M. Swain. 'Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.' Nature Reviews Cancer 9.7 (2009): 463-475.
- Baselga, José, et al. 'Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.' Journal of clinical oncology 23.24 (2005): 5568-5577.
- Baselga, Jose, et al. 'Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.' Journal of clinical oncology 20.21 (2002): 4292-4302.
- Baselga, Jose. 'The EGFR as a target for anticancer therapy—focus on cetuximab.' European journal of cancer 37 (2001): 16-22.
- Baselga, Jose, et al. 'Phase I studies of anti–epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.' Journal of Clinical Oncology 18.4 (2000): 904-904.
- Baselga, Jose, et al. 'Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.' Cancer research 58.13 (1998): 2825-2831.
